Rigel Pharma (NASDAQ: RIGL) reported Q2 EPS of $0.04, $0.12 better than the analyst estimate of ($0.08). Revenue for the quarter came in at $26.89 million versus the consensus estimate of $25.7 million.

For earnings history and earnings-related data on Rigel Pharma (RIGL) click here.